How should I switch from Focalin (dexmethylphenidate) 15 mg twice daily to Vyvanse (lisdexamfetamine)?

Switching from Focalin 15 mg BID to Vyvanse

Start Vyvanse at 30 mg once daily in the morning, which represents a conservative initial dose when switching from dexmethylphenidate 30 mg/day total, then titrate by 10-20 mg weekly based on response up to a maximum of 70 mg daily. 1

Rationale for Starting Dose

Your current Focalin (dexmethylphenidate) dose of 15 mg twice daily equals 30 mg total daily. Dexmethylphenidate is the active d-isomer of methylphenidate, while Vyvanse (lisdexamfetamine) is a prodrug that converts to dextroamphetamine. These are different stimulant classes—methylphenidate versus amphetamine—so direct dose conversion is not straightforward.

The FDA-approved starting dose for Vyvanse is 30 mg once daily for ADHD treatment in adults and children 6 years and older 1. This represents a reasonable and safe starting point when switching between stimulant classes, as it allows assessment of tolerability and response to the amphetamine mechanism without overshooting.

Switching Protocol

Immediate Switch Approach

• Discontinue Focalin and start Vyvanse 30 mg the next morning
• No tapering of Focalin is required—stimulants can be stopped abruptly without withdrawal syndrome
• Take Vyvanse in the morning with or without food; avoid afternoon dosing due to insomnia risk 1

Titration Schedule

• Week 1-2: Vyvanse 30 mg once daily (assess tolerability and initial response)
• Week 3+: If inadequate response and good tolerability, increase by 10-20 mg weekly 1
• Target range: 50-70 mg daily for most patients
• Maximum dose: 70 mg daily 1

The weekly titration intervals allow adequate time to assess response, as Vyvanse provides 11-13 hours of symptom control 2, 3.

Key Differences to Anticipate

Duration of Action

• Focalin: Immediate-release lasts ~4 hours; extended-release lasts ~8 hours with twice-daily dosing providing coverage
• Vyvanse: Single daily dose provides 11-13 hours of coverage 2, 3
• Vyvanse has a 2-hour onset (slower than immediate-release Focalin) due to prodrug activation 2

Mechanism Differences

Lisdexamfetamine is a prodrug requiring enzymatic cleavage of lysine in red blood cells to release active dextroamphetamine 4, 5. This provides more consistent absorption and potentially lower abuse liability compared to immediate-release amphetamines 3. The amphetamine class may have different efficacy and side effect profiles compared to methylphenidate derivatives.

Monitoring and Adjustment

What to Monitor

• Cardiovascular: Blood pressure and heart rate at each visit (amphetamines can cause increases) 1
• Psychiatric: Mood changes, anxiety, irritability, or aggression 6
• Sleep: Insomnia is common (28.7% in studies); ensure morning dosing 6
• Appetite/Weight: Decreased appetite occurs in 62.4% of patients; monitor weight 6
• Efficacy: ADHD symptom control throughout the day

Common Pitfalls

1. Starting too high: Some clinicians attempt 1:1 dose equivalence, but stimulant classes differ—start conservatively
2. Inadequate trial duration: Allow at least 1 week at each dose before increasing 1
3. Late-day dosing: Vyvanse's long duration makes afternoon doses problematic for sleep
4. Expecting immediate equivalence: 41% of patients switching stimulants require changes due to tolerability 7; be prepared to adjust

When Switching May Not Work

Research shows that 41% of medication-naïve adults required switching between methylphenidate and amphetamine families due to poor tolerability 7. Additionally, 74.4% of discontinuations from lisdexamfetamine were due to adverse effects 6.

If Vyvanse is not tolerated or effective after adequate trial (4-6 weeks at optimal dose):

• Consider switching back to methylphenidate class (different formulation)
• Consider non-stimulant options (atomoxetine, guanfacine)
• Evaluate for comorbid conditions affecting response

Special Considerations

Renal Impairment

If creatinine clearance is reduced, maximum Vyvanse dose should be limited to 50 mg daily (severe impairment) or 30 mg daily (ESRD) 1.

Drug Interactions

• Avoid MAOIs: Do not use within 14 days of MAOI discontinuation 1
• Urinary pH: Alkalinizing agents increase amphetamine levels; acidifying agents decrease them 1
• Serotonergic drugs: Monitor for serotonin syndrome if combining with SSRIs/SNRIs 1

Pregnancy/Breastfeeding

Limited data suggest no major teratogenic effects from lisdexamfetamine, though it is a prodrug of dextroamphetamine 5, 8. Discuss risks/benefits if applicable.